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ABSTRACT 
Pink1 has been linked to both autosomal reces- 
sive and sporadic forms of Parkinson disease. 
The Pink1 protein is thought to be involved in 
mitochondrial protection by interacting with 
parkin to prevent oxidative damage, maintain 
mitochondrial integrity and regulate mitophagy. 
Pink1 and parkin have been linked to compo- 
nents of the insulin receptor (INR) pathway, in- 
cluding PTEN, Akt and Foxo, but their effects in 
the INR pathway have been largely overlooked. 
To further investigate the roles of Pink1/parkin, 
we have performed co-expression studies to de- 
termine the effects Pink1 and parkin on the 
Foxo-induced phenotype of developmental de- 
fects in the Drosophila eye. We examined di- 
rected expression of Pink1, parkin, Pink1 or 
parkin mutants, and Pink1 or parkin interfering 
RNAs (RNAi) with the overexpression of Foxo in 
the developing eye of Drosophila. Our findings 
show that reduction of Pink1 suppresses the 
effects of Foxo overexpression, where co-overex- 
pression with Pink1 or parkin increases the se- 
verity of the phenotype. This suggests that 
Pink1 and parkin are able to increase the pro- 
apoptotic effects of Foxo. Contrary to the view 
that Pink1 and parkin act exclusively as protec- 
tive proteins in the cell, it is likely that the 
Pink1/parkin pathway is involved in aspects of 
cell fate decisions other than degrading toxic 
proteins and maintaining mitochondrial integ- 
rity. 
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1. INTRODUCTION 
Pink1 (PTEN induced putative kinase 1) encodes a 
serine-threonine kinase which has been linked to auto- 
somal recessive and some sporadic forms of Parkinson 
disease [1-3]. Targeted to the mitochondria, Pink1 is 
thought to be involved in mitochondrial protection by 
preventing oxidative damage and maintaining mitochon- 
drial integrity, where loss of function of Pink1, in hu- 
mans and in Drosophila melanogaster, show substantial 
mitochondrial defects in sensitive tissues [4-8]. It is be- 
coming increasingly apparent that protection during cell 
stress is due to the involvement of Pink1 in mitochon- 
drial fission/fusion events [1,9]. This involvement im- 
plicates Pink1 as a key regulator of fission/fusion, acting 
upstream of the E3 ubiquitin ligase, parkin, to maintain 
proper mitochondrial integrity and function [4,6,10,11]. 
In this role, recruitment of parkin to the mitochondria by 
Pink1 results in the ubiquitination of various mitochon- 
drial proteins, promoting fission and mitophagy [12-15]. 
In contrast, studies have found that loss of parkin or 
Pink1 function can also result in increased fission, pro- 
moting mitophagy [16,17]. Although the fission/fusion 
decision is not fully understood, results do highlight the 
importance of the Pink1/parkin pathway in maintaining 
mitochondrial homeostasis. 
The Pink1/parkin pathway has been linked to compo- 
nents of the insulin receptor (INR) pathway, including: 
interaction of PTEN with Pink1 [18] and DJ-1 [19,20], 
an indirect interaction with Akt through parkin [21], an 
interaction with Akt through DJ-1 [22,23], and transact- 
tivation of Pink1 by Foxo [24,25]. It has also been sug- 
gested that Pink1 may activate Foxo indirectly through 
Sir2 [26]. This is thought to be a protective mechanism, 
where Foxo activation results in the transcription of 
genes such as SOD2 and Thor. In addition to genes that 
promote stress resistance, under conditions of oxidative 
stress or starvation, Foxo transcription factors may also 
target genes that promote cell cycle arrest and apoptosis 
[27,28]. Overexprssion of Foxo has been linked to neu- 
rotoxicity [29,30] and overexpression in the developing 
Drosophila eye results in a characteristic phenotype with 
reductions in cell number and area [31]. Genetic expres- 
sion studies using the fly eye have been enormously 
successful in the study of neurodegeneration. This is due 
to the conservation of key signaling pathways between 
humans and Drosophila, and the ease of quantifying de- 
generation of photoreceptor neurons associated with each 
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Drosophila ommatidium. To further investigate the roles 
of Pink1/parkin, we have performed expression studies 
to determine the effects of Pink1 and parkin on the 
Foxo-induced phenotype of developmental defects in the 
Drosophila eye. We hypothesized that through an inter- 
action with the INR pathway, or through mitochondrial 
protective effects, Pink1 and parkin would be capable of 
alleviating the detrimental effects of Foxo overexpres- 
sion. In contrast, our findings show that reduction of 
Pink1 is able to suppress the effects of Foxo overexpres- 
sion, where co-overexpression of Foxo with Pink1 or 
parkin results in an increased severity of the Foxo-in- 
duced phenotype. These findings suggest a complex role 
for the Pink1/parkin pathway in cell fate decisions. 
2. MATERIALS AND METHODS 
2.1. Fly Stocks and Culture 
The UAS-Pink1 transgenic line was created from the 
GH20931 Drosophila melanogaster Pink1 clone [32]. 
The UAS-murine Foxo1 (UAS-Foxo) and UAS-murine 
Foxo1AA (UAS-FoxoAA) transgenes are described in Kra- 
mer et al. [31] and the GMR-Gal4 UAS-Foxo and GMR- 
Gal4;UAS-FoxoAA lines were established through stan- 
dard means. UAS-parkin was created previously in our 
laboratory [33]. The Pink1B9 mutant line was provided by 
Dr. J. Chung [6]. The UAS-Pink1RNAi and UAS- park-
inRNAi lines were provided by Dr. B. Lu [7,34]. The UAS- 
GFP control was obtained from the Bloomington stock 
centre. The parkin45 mutant line was provided by Dr. L. 
Pallanck [35]. All crosses were performed using standard 
techniques. All flies were cultured on standard corn- 
meal/yeast/molasses/agar media at 25˚C. 
2.2. Scanning Electron Microscopy of the 
Drosophila Eye 
Flies were aged three days past eclosion on standard 
cornmeal/yeast/molasses/agar media at 25˚C. Flies were 
then frozen at −80˚C and examined under dissecting mi- 
croscope. Flies were mounted, desiccated overnight and 
coated in gold before photography at 170 times magnifi- 
cation with a Hitachi S-570 SEM. Area of the eye was 
measured as per the ocular area, regardless of the pres- 
ence of ommatidia. This was determined by outlining the 
ocular margin and/or ridge bristles indicating the posto- 
cular area. Eye areas and ommatidial counts were com- 
pared using GraphPad Prism 5, using unpaired t-test with 
a significance level of 0.05. 
3. RESULTS 
3.1. Parkin Increases the Severity of the 
Foxo-Induced Phenotype 
Overexpression of Foxo in the developing Drosophila 
eye results in a characteristic phenotype with reductions 
in cell number and area [31]. When co-overexpressed 
with parkin, there is a significant increase in the severity 
of the Foxo-induced phenotype (Figure 1), including a 
significant reduction in number of ommatidia and overall 
area of the eye (p < 0.0001, df = 31). This suggests that 
the addition of parkin further reduces the number of via- 
ble cells available during eye development. Co-over- 
expression with Pink1 shows no significant increase in 
the Foxo-induced reduction of ommatidia (p = 0.1150, df 
= 29) and area (p = 0.2335, df = 29) (Figure 1). 
3.2. Reduction in Pink1 Decreases the  
Severity of the Foxo-Induced Phenotype 
Overexpression of Foxo in a Pink1 mutant background 
(Pink1B9) results in a significant increase in ommatidia 
number (p = 0.0008, df = 21) and eye area (p = 0.0015, 
df = 21) (Figure 2). In addition, co-overexpression of 
Foxo with Pink1RNAi shows an even greater effect, with 
significant increases in ommatidia number and area (p < 
0.0001, df = 30) (Figure 2). These results suggest that 
the absence or depletion of Pink1 during eye develop- 
ment is able to alleviate the detrimental effects of Foxo. 
Overexpression of Foxo in a parkin mutant background 
(parkin45) or co-overexpression with parkinRNAi resulted  
 
 
(a) 
 
(b)                          (c) 
Figure 1. Parkin increases the severity of the Foxo-induced 
phenotype. Co-overexpression of Foxo with parkin shows a 
significant reduction in number of ommatidia and overall area 
of the eye. Co-overexpression of Foxo with Pink1 shows no 
significant increase in the Foxo-induced reduction of om- 
matidia and area. Genotypes shown include GMR-Gal4 UAS- 
Foxo/UAS-GFP (Foxo + GFP), GMR-Gal4 UAS-Foxo/+; UAS- 
Pink1/+ (Foxo + Pink1), GMR-Gal4 UAS-Foxo/+; UAS-par- 
kin/+ (Foxo + parkin). Error bars indicate standard error of the 
mean. 
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Figure 2. Reduction in Pink1 decreases the severity of the 
Foxo-induced phenotype. Overexpression of Foxo in the Pink1 
mutant background (Pink1 B9) results in a significant increase 
in ommatidia number and eye area. Co-overexpression of Foxo 
with Pink1RNAi (Pink1 RNAi) shows significant increases in 
ommatidia number and area. Overexpression of Foxo in a 
parkin mutant background (GMR-Gal4 UAS-Foxo/+; parkin45/ 
parkin45) or co-overexpression with parkinRNAi (GMR-Gal4 
UAS-Foxo/+; parkinRNAi/+) resulted in apparent synthetic le- 
thality. Genotypes shown include GMR-Gal4 UAS-Foxo/UAS- 
GFP (Foxo + GFP), GMR-Gal4 UAS-Foxo/+; UAS-Pink1RNAi/ 
+ (Foxo + Pink1 RNAi), Pink1B9/y;GMR-Gal4 UAS-Foxo/+ 
(Foxo + Pink1 B9).  Error bars indicate standard error of the 
mean. 
 
in apparent synthetic lethality with no surviving progeny. 
This implies that the broad protective functions of parkin 
are necessary to maintain a viable organism during this 
development. 
3.3. Effects of Pink1 and Parkin on the 
Foxo-Induced Phenotype are  
Independent of Akt Signalling 
The constitutively active version of Foxo (FoxoAA) 
contains an alanine substitution at the T1 (T24A) and S1 
(S253A) Akt phosphorylation sites [36]. Using FoxoAA, 
the severity of the Foxo-induced phenotype was seen to 
increase with Pink1 or parkin co-overexpression (Figure 
3). Co-overexpression of Pink1 with FoxoAA results in 
significant decreases in number of ommatidia and eye 
area (p < 0.0001, df = 30). Co-overexpression of parkin 
with FoxoAA also results in significant decreases in num- 
ber of ommatidia (p = 0.0090, df = 29) and eye area (p = 
0.0190, df = 29). The apparent rescue of the Foxo-in- 
duced phenotype, seen when co-overexpressing Foxo  
 
(a) 
 
 
(b)                          (c) 
Figure 3. Effects of Pink1 and parkin on the Foxo-induced 
phenotype, independent of Akt signalling. Co-overexpression 
of FoxoAA (FoxoAA) with Pink1 results in significant decreases 
in number of ommatidia and eye area. Co-overexpression of 
FoxoAA with parkin results in significant decreases in number 
of ommatidia and eye area. Genotypes shown include GMR- 
Gal4/UAS-GFP;UAS-FoxoAA/+ (FoxoAA + GFP), GMR-Gal4/ 
+; UAS-FoxoAA/UAS-Pink1 (FoxoAA + Pink1), GMR-Gal4/+; 
UAS-FoxoAA/UAS-parkin (FoxoAA + parkin). Error bars indi- 
cate standard error of the mean. 
 
with Pink1RNAi (Figure 2), is maintained when using the 
constitutively active version, FoxoAA (Figure 4). Co- 
overexpression of FoxoAA with Pink1RNAi results in a dra- 
matic increase in ommatidia number and eye area (p < 
0.0001, df = 30). These results indicate that the Pink1/ 
parkin interaction with Foxo is independent of Akt sig- 
nalling. In contrast, there is no significant difference in 
ommatidia number (p = 0.2131, df = 29) or eye area (p = 
0.8027, df = 29) when FoxoAA is overexpressed in the 
Pink1B9 mutant background (Figure 4). As seen with 
Foxo overexpression, co-overexpression of FoxoAA with 
parkinRNAi resulted in apparent synthetic lethality with no 
surviving progeny. 
4. DISCUSSION 
Under cell stress conditions, Foxo transcription factors 
are activated and target genes that promote cell survival 
and/or apoptosis [27,28]. The transactivation of Pink1 by 
Foxo [24,25] suggests that there may be recruitment of 
the Pink1/parkin pathway to help maintain mitochondrial 
homeostasis during cell stress. Acting in this protective 
role, we hypothesized that Pink1 and parkin may allevi- 
ate the Foxo-induced phenotype of developmental de- 
fects in the Drosophila eye. This would presumably be  
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Figure 4. Effects of reductions in Pink1 on the Foxo-induced 
phenotype, independent of Akt signalling. Co-overexpression 
of FoxoAA (FoxoAA) with Pink1RNAi (Pink1 RNAi) results in a 
dramatic increase in ommatidia number and eye area. Overex- 
pression of FoxoAA in the Pink1 mutant background (Pink1 B9) 
is not significantly different from the control. Co-overexpression 
of FoxoAA with with parkinRNAi (GMR-Gal4/+; UAS-FoxoAA/ 
parkinRNAi/+) resulted in apparent synthetic lethality. Geno- 
types shown include GMR-Gal4/UAS-GFP; UAS-FoxoAA/+ 
(FoxoAA + GFP), GMR-Gal4/+; UAS-FoxoAA/UAS-Pink1RNAi 
(FoxoAA + Pink1 RNAi), Pink1B9/y; GMR-Gal4/+; UAS-FoxoAA/ 
+ (FoxoAA + Pink1 B9). Error bars indicate standard error of 
the mean. 
 
due to the regulation of mitochondrial fission/fusion ev- 
ents and through mitophagy to degrade dysfunctional mi- 
tochondrial fragments, maintaining the overall mito- 
chondria health of the cell [1,9]. In contrast, our results 
indicate that the Pink1/parkin pathway may be involved 
in aspects of cell fate other than protection. Our findings 
show that co-overexpression of Pink1 or parkin results in 
an increased severity of the Foxo-induced phenotype, 
and that a reduction in Pink1 is able to improve on the 
phenotype. This suggests that there may be a more com- 
plex role for the Pink1/parkin pathway under cell stress 
conditions. 
Many transcriptional targets of Foxo have been identi- 
fied, including molecules involved in metabolism, oxida- 
tive stress resistance, cell cycle arrest and apoptosis 
[27,28]. The Foxo-induced phenotype of developmental 
defects in the Drosophila eye is likely due to the tran- 
scription of pro-apoptotic gene targets. Drosophila stud- 
ies link phosphorylation of Foxo to neurodegeneration, 
and have identified the pro-apoptotic Hid gene as one 
responsible target, where overexpression of Hid causes 
dramatic eye degeneration [29,30,37]. In contrast, Foxo 
has also been shown to prevent mitochondrial dysfunc- 
tion and neurodegeneration, and is proposed to function 
downstream of Pink1 [26]. In this protective role, Foxo is 
thought to act through targets including the mitochon- 
drial superoxide dismutase SOD2, a gene involved in 
stress resistance. With the ability to promote cell survival 
or apoptosis, changes in Foxo activity may be the me- 
chanism behind the effects of Pink1 and parkin on the 
Foxo-induced phenotype. Co-overexpression of Pink1 or 
parkin may affect Foxo activity to increase the tran- 
scription of pro-apoptotic targets, thus increasing the 
severity of the phenotype. Improvement of the Foxo- 
induced phenotype seen with reductions in Pink1 may 
also indicate a change in Foxo activity, suggesting that 
the relationship between Pink1 and Foxo is more com- 
plex than Pink1 indirectly activating Foxo downstream. 
It is also possible that Pink1 and parkin are acting out- 
side of the INR pathway to affect cell survival. The in- 
fluence of Pink1 and parkin on mitofission/mitofusion 
events is not fully understood, and some mechanisms 
involved are closely tied to apoptosis. It may be that un- 
der certain conditions these mechanisms are utilized to 
promote apoptosis instead of cell protection. One exam- 
ple would be the ubiquitination of VDAC by parkin [14]. 
VDAC is a major component of the permeability transi- 
tion pore (PTP), and is involved with mitochondrial outer 
membrane permeabilization (MOMP) through interact- 
tions with pro-apoptotic Bcl-2 proteins [38]. With both 
the PTP and MOMP implicated as initiators of apoptosis, 
mitofission events triggered by ubiquitination of VDAC 
must be controlled so to prevent release of apoptotic 
factors from the mitochondria. Compounding factors, 
such as the effects of Hid in the Foxo-induced phenotype, 
may result in overwhelming instability during increases 
in Pink1 or parkin expression, making this degree of 
control impossible. In this instance, Pink1 and parkin 
may actively participate in the initiation of apoptosis, a 
novel role for the Pink1/parkin pathway that warrants 
further investigation.  
Expression of the constitutively active version of Foxo 
(FoxoAA) with co-overexpression of Pink1, parkin or 
Pink1RNAi seems to indicate that the Pink1/parkin effect 
on the Foxo-induced phenotype is independent of Akt 
signalling, supporting the idea that Pink1 and parkin may 
be acting outside of the INR pathway. In contrast, the 
change in significance when expressing FoxoAA in the 
Pink1B9 mutant background suggests that there is Akt 
involvement. Interestingly, this may indicate that there is 
a role for Pink1 in the cell that is independent of its ki- 
nase function, and that this additional role is somehow 
involved in the Akt signalling pathway. In this respect, 
the apparent rescuing effect of the Foxo-induced phenol- 
type during decreases in Pink1 expression would be par- 
tially due to the decrease in kinase activity, and partially 
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due to the presence of the Pink1 protein. Future studies 
looking into an additional role for Pink1, apart from its 
kinase function, may yield new interactions and targets 
in the Pink1/parkin pathway. 
5. CONCLUSION 
In conclusion, our results show that Pink1 and parkin 
are able to increase the effects of Foxo in Drosophila, 
highlighting a possible role for the Pink1/parkin pathway 
in cell death. In addition, the constitutively active version 
of Foxo allows us to exclude a general requirement for 
Akt during increased expression of Pink1 or parkin, 
however, suggests that there may be an additional role 
for Pink1 apart from its kinase function. Further studies 
looking at the effect of Pink1 and/or parkin on Foxo ac- 
tivity, and the role of the Pink1/parkin pathway in mito- 
chondrial fission/fusion events, may uncover underlying 
mechanisms that mediate a shift towards apoptosis. 
Moreover, it is likely that the Pink1/parkin pathway is 
involved in various aspects of cell fate decisions, con- 
trary to the view that Pink1 and parkin act exclusively as 
protective proteins. 
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